CLINICAL TRIALS PROFILE FOR SODIUM IODIDE I 123

All Clinical Trials for SODIUM IODIDE I 123

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00450814 ↗	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-11-30	This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.
NCT00450814 ↗	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	Completed	Mayo Clinic	Phase 1/Phase 2	2006-11-30	This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	National Institute for Health Research, United Kingdom	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	University of Dundee	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	University of Oxford	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00725946 ↗	Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT	Terminated	Stanford University	Early Phase 1	2008-02-01	This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by immunohistochemical methods. A total of 10 patients will be imaged with 124I PET/CT (serial scans over 24 hour period) to determine radioiodide uptake and distribution in tumor tissue. Thyroid iodide uptake and retention will be blocked beginning one week prior to 124I PET/CT scan with thyroid hormone (T3) and methimazole (impedes organification). Tumor, organ and whole body dosimetry will be calculated in each patient.
NCT00788307 ↗	Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy	Terminated	National Cancer Institute (NCI)	Phase 1	2008-11-03	RATIONALE: Radioactive drugs, such as radioactive iodine, may carry radiation directly to tumor cells and not harm normal cells. Placing a gene called Ad5CMV-NIS in prostate cancer cells may help the prostate cells take in more radioactive iodine and thus kill the cancer cells. Drugs, such as liothyronine sodium, may protect the thyroid from the side effects of radioactive iodine. PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy given together with radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy.

Clinical Trial Conditions for SODIUM IODIDE I 123

Condition Name

Condition Name for SODIUM IODIDE I 123
Intervention	Trials
Breast Cancer	4
Recurrent Plasma Cell Myeloma	2
Refractory Plasma Cell Myeloma	2
Ovarian Endometrioid Adenocarcinoma	2

Condition MeSH

Condition MeSH for SODIUM IODIDE I 123
Intervention	Trials
Breast Neoplasms	4
Neoplasms, Plasma Cell	3
Multiple Myeloma	3
Carcinoma	3

Clinical Trial Locations for SODIUM IODIDE I 123

Trials by Country

Trials by Country for SODIUM IODIDE I 123
Location	Trials
United States	13
United Kingdom	3
Canada	2
Korea, Republic of	2
Japan	1

Trials by US State

Trials by US State for SODIUM IODIDE I 123
Location	Trials
Minnesota	6
Florida	2
Arizona	2
California	2
Arkansas	1

Clinical Trial Progress for SODIUM IODIDE I 123

Clinical Trial Phase

Clinical Trial Phase for SODIUM IODIDE I 123
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 2	4

Clinical Trial Status

Clinical Trial Status for SODIUM IODIDE I 123
Clinical Trial Phase	Trials
Recruiting	7
Terminated	4
Completed	4

Clinical Trial Sponsors for SODIUM IODIDE I 123

Sponsor Name

Sponsor Name for SODIUM IODIDE I 123
Sponsor	Trials
Mayo Clinic	6
National Cancer Institute (NCI)	5
Stanford University	2

Sponsor Type

Sponsor Type for SODIUM IODIDE I 123
Sponsor	Trials
Other	22
NIH	5
Industry	1

Sodium Iodide I 123: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is sodium iodide I-123 and what does it treat?

Sodium iodide I-123 is a diagnostic radiopharmaceutical used in nuclear medicine. It is administered to support thyroid imaging, uptake, and related diagnostic workflows where iodine-123 is the radiotracer. The product is used for imaging rather than to treat a disease directly.

What is the current clinical-trials activity landscape?

No complete, reliable, citable clinical-trials dataset is available in the provided material for sodium iodide I-123. Without access to a validated registry extract (for example, ClinicalTrials.gov with specific query results), a complete and accurate “clinical trials update” cannot be produced.

Where is sodium iodide I-123 sold and who buys it?

The market is driven by:

• Nuclear medicine practices and imaging centers.
• Hospital radiology departments.
• Specialized distributors that handle short shelf-life logistics for radiopharmaceuticals.
• Physician-directed referral patterns for thyroid diagnostics.

Procurement is strongly structured around imaging demand and radiopharmacy supply continuity, since radiotracer availability and chain-of-custody logistics determine usable inventory windows.

How does the market get sized for I-123 sodium iodide?

A defensible market sizing method for radiopharmaceuticals is based on:

• Annual administered doses (imaging procedures) for thyroid and related diagnostic indications.
• Pricing per administered dose or per kit/vial equivalent (varies by regional procurement and radiopharmacy contracts).
• Supply constraints tied to generator production cycles and radiopharmaceutical manufacturing capacity.
• Competitive intensity (generic vs. innovator competition is common in older radiotracer products, but practical availability determines realized pricing).

However, no numerical market baseline, pricing dataset, dose-volume data, or validated forecasts are present in the provided material. A complete and accurate market analysis and projection cannot be produced without citable figures.

What are the main demand drivers?

Demand is primarily tied to:

• Ongoing incidence and diagnostic throughput for thyroid disorders (including routine workups).
• Physician adoption of I-123-based uptake and imaging protocols relative to alternatives (other tracers and ultrasound/CT workflows).
• Patient scheduling patterns that rely on dependable radiotracer supply.
• Health system volume: outpatient imaging growth and hospital nuclear medicine throughput.

Counterweights:

• Substitution by other imaging modalities in certain pathways.
• Radiopharmaceutical supply disruptions or manufacturing constraints that reduce usable inventory.
• Reimbursement pressure that caps effective net pricing.

What are the main supply and regulatory constraints?

Radiopharmaceutical supply constraints that typically shape near-term availability and realized revenue include:

• Manufacturing throughput and batch release timing.
• Quality system controls and cold-chain/logistics performance.
• Regional regulatory compliance and distribution licensing.
• Dependence on upstream radionuclide supply and production economics.

Because sodium iodide I-123 is a radiotracer product, supply volatility can have an outsized effect on commercial outcomes in periods of shortage.

Competitive dynamics: how does this product compete?

In radiopharmaceuticals, competition is usually determined by:

• Availability (can sites consistently obtain usable doses when scheduled?).
• Total cost to procure and administer (including delivery time and operational overhead).
• Net price after contracting and wholesaler terms.
• Reliability of supply and regulatory track record.

In many markets, the practical differentiators are continuity of supply and delivery lead time rather than claims-based differentiation.

Market projection framework (what would be projected, and how)

A robust projection for sodium iodide I-123 would model three variables over a multi-year horizon:

1. Procedure volume trend (drivers: incidence, adoption, outpatient throughput; dampers: modality substitution).
2. Net pricing trend (drivers: contracting, reimbursement, competitive entry; dampers: generics/price erosion in mature products).
3. Supply availability factor (drivers: production stability and capacity; dampers: shortages).

Without market input data and citations, no quantitative projection can be stated.

Business implications (actionable, but data-bound)

Because this request requires a “clinical trials update, market analysis and projection,” the business implications depend on validated registry and market datasets. Those datasets are not included in the provided material, so an accurate, citable plan cannot be delivered.

Key Takeaways

• Sodium iodide I-123 is a diagnostic radiopharmaceutical used for thyroid imaging/uptake workflows.
• A complete clinical-trials update cannot be generated without a citable registry extract.
• A complete market analysis and numerical projections cannot be produced without validated market sizing, pricing, and forecast inputs.

FAQs

1) Is sodium iodide I-123 a treatment or a diagnostic agent?
It is a diagnostic radiopharmaceutical used for imaging workflows.

2) What determines commercial performance for I-123 sodium iodide?
Demand for thyroid diagnostics and dependable radiotracer supply and logistics drive performance.

3) What types of clinical studies are typically relevant for radiopharmaceuticals like this?
Studies commonly include diagnostic performance, imaging protocols, dosimetry, and usability/safety in labeled populations.

4) How is the market usually sized for radiopharmaceuticals?
By annual administered dose/procedure counts and net realized pricing under contracting and reimbursement frameworks.

5) What most affects short-term revenue for radiotracers?
Supply availability, batch release timing, and distribution lead times that affect usable inventory.

References

[1] No sources were provided in the prompt.